CASE REPORT

Coronavirus disease-19 encephalitis as a differential diagnosis of a cyclosporine related posterior leukoencephalopathy syndrome: A case report

Une encéphalite à coronavirus-19 comme diagnostic différentiel d'un syndrome de leucoencéphalopathie postérieure lié à la cyclosporine: Un cas clinique

Sanda Mrabet[1], Achraf Jaziri[1], Maha Aroud[1], Dorsaf Zellama[1], Salma Naija[2], Sana Ben Amor[2], Alaa Souissi[3], Hela Jemni[3]

1. Department of Nephrology, Dialysis, and transplantation. Sahloul University Hospital. Sousse. Tunisia
2. Department of Neurology. Sahloul University Hospital. Sousse. Tunisia.
3. Department of Radiology. Sahloul University Hospital. Sousse. Tunisia.

Abstract

Introduction: Posterior leukoencephalopathy syndrome (PRES) is a rare neurological disease possibly associated with the use of calcineurin inhibitors like cyclosporine A (CSA). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for the outbreak of coronavirus disease 19 (COVID-19) can cause neurological manifestations. We described a case of CSA-related PRES whose diagnosis was difficult due to a concurrent infection with SARS-CoV-2.

Observation: The 16-year-old patient was known to have corticosteroid-resistant nephrotic syndrome secondary to minimal change disease. CSA was introduced, and on the fifth day of treatment, the patient presented with seizures followed by fever. Biological and magnetic resonance imaging data were in favor of SARS-CoV-2 encephalitis. Relief of immunosuppression by discontinuation of CSA was decided and the patient was put on anticonvulsants. After being declared cured of COVID-19, which was without other clinical signs, the CSA was reintroduced but the patient presented with seizures the next day. This allowed the physicians to rectify the diagnosis and relate the seizures to a CSA-related PRES.

Conclusion: Infection with SARS-CoV-2 could be a differential diagnosis of a PRES related to calcineurin inhibitors.

Key words: Calcineurin inhibitors, encephalopathy, glomerulonephritis, virus infection

Résumé

Introduction: Le syndrome de leucoencéphalopathie postérieure (PRES) lié à la cyclosporine est une maladie neurologique rare pouvant compliquer le traitement par les inhibiteurs de la calcineurine comme la cyclosporine A (CSA). Le coronavirus 2 du syndrome respiratoire aigu sévère (SARS-CoV-2) responsable de l'épidémie de la maladie à coronavirus 19 (COVID-19) peut provoquer des manifestations neurologiques. Nous décrivons un cas de PRES lié à la CSA dont le diagnostic était difficile en raison d'une infection concomitante par le SARS-CoV-2.

Observation: Un patient de 16 ans souffrait d'un syndrome néphrotique corticorésistant secondaire à des lésions glomérulaires minimes. La CSA a été introduite et au cinquième jour du traitement, le patient a présenté des convulsions suivies de fièvre. Les données biologiques et celles de l'imagerie par résonnance magnétique étaient en faveur de l'encéphalite à SARS-CoV-2. L'arrêt de la CSA a été décidé et le patient a été mis sous anticonvulsivants. Après l'infection à COVID-19, la CSA a été réintroduite mais le patient a présenté des convulsions le lendemain. Cela a permis aux médecins de rectifier le diagnostic et de relier les crises à un PRES lié à la CSA.

Conclusion: L'infection par le SARS-CoV-2 pourrait constituer un diagnostic différentiel d'un PRES lié aux anticalcineurines.

Mots clés: encéphalopathie ; glomerulonéphrite ; inhibiteurs de la calcineurine ; infection virale

Correspondance
Sanda Mrabet
Department of Nephrology, Dialysis, and transplantation. Sahloul University Hospital. Sousse. Tunisia
Email: mrabet1sanda@gmail.com

LA TUNISIE MEDICALE-2024; Vol 102 (07): 429-432 DOI: 10.62438/tunismed.v102i7.5027

Introduction

Posterior leukoencephalopathy syndrome (PRES) is a serious neurological disorder of (sub) acute onset characterized by abnormalities in cerebral white matter (1). Clinical symptoms may include headaches, visual disturbances, disorders of consciousness, seizures, or focal neurological deficits (2). Cytotoxic medicine, (pre) eclampsia, sepsis, renal disorders, or autoimmune disorders are common conditions in which PRES develops (1).

Among drugs, PRES may complicate calcineurin inhibitors such as cyclosporine A (CSA) (3). Organ-transplanted patients and those with nephrotic syndrome (NS) on this drug have reportedly experienced this complication (3-5).

This article reported a unique and challenging case of a 16-year-old boy admitted to our department with steroid-resistant nephrotic syndrome (NS) and coronavirus disease -19 (COVID-19) in February 2022. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection misled the diagnosis of CSA-induced PRES.

Case report

The patient is a 16-year-old Tunisian boy known for nephrotic syndrome (NS) related to a minimal change disease diagnosed based on a renal biopsy in October 2021.

In February 2022, the patient was admitted to the Nephrology department for a corticosteroid-resistant NS with severe adverse events of glucocorticoids (Cushing syndrome, glaucoma, and dyslipidemia). On clinical examination, the boy's weight and height were 75 kg and 1.68 m, respectively. The patient was afebrile and had no respiratory symptoms. His systolic and diastolic blood pressure were 130 and 70 mmHg, respectively, with a heart rate of 80 bpm. The patient had lower limb edema related to his NS. Regarding his corticosteroid NS, we decided to start CSA treatment at a dose of 3 mg/kg/day with progressive tapering of corticosteroids.

On the fifth day of CSA start, the patient presented two short left clonic focal seizures with a duration inferior to two minutes. After one minute, the patient had a third motor focal onset seizure with secondary generalization and conscious alteration. The recovery of consciousness was after 30 minutes. Apart from a high C-reactive protein, biological tests were in the normal range and could not explain these symptoms (Table 1).

Table 1. Results of blood tests of the patient with nephrotic syndrome and seizures.

Blood analysis	Findings	Normal range
Sodium (mmol/L)	127	136-146
Potassium (mmol/L)	3.4	3.5-5.1
Chlore (mmol/L)	90	101-109
Total Protein (g/L)	57	66-83
Albumin (g/L)	27	36-48
Calcium (mmol/L)	2.11	2.15-2.5
Magnesium (mmol/L)	0.7	0.743-1.06
C-reactive protein (mg/L)	102	<8
Glucose (mmol/L)	7.9	3.6-6.1

Intravenous sodium valproate was initiated quickly and we have not objectified a new seizure. The cranial magnetic resonance imaging (MRI) showed leptomeningeal enhancement with a predilection in the cerebellar hemispheres (Figure 1).



Figure 1. Bilateral cerebellarfolia hyperintensities in axial Fluid attenuated inversion recovery – weighted magnetic resonance imaging sequences (A), these lesions showed hypointensities on gradient-echo sequences (B) and leptomeningeal gadolinium enhancement (C).

The cerebrospinal fluid analysis (CSF) showed normal cellularity with hyperproteinorachia (Table 2), and the CSF bacterial culture was negative.

Table 2. Results of cerebrospinal fluid tests of the patient with nephrotic syndrome and seizures.

Cerebrospinal fluid analysis	Findings	Normal range
Appearance	Transparent	Transparent
Glucose (mmol/L)	2.2	2.5-3.5
Protein (g/L)	0.71	0.18-0.45
Chlore (mmol/L)	122	117-127
White blood cell ($x10^6$/L)	<1	<5 cells
Red blood cell ($x10^6$/L)	<1	<10 cells
Culture	Negative	Negative
RT-PCR for SARS-COV-2	Negative	Negative

RT-PCR: Reverse transcription polymerase chain reaction. **SARS-COV-2**: Severe acute respiratory syndrome coronavirus 2.

The patient experienced sinus tachycardia, with one episode of fever. Therefore, we decided to perform nasopharyngeal reverse transcription polymerase chain reaction (RT-PCR) for SARS-CoV-2 since the patient was in contact with a COVID-19 subject. The test returned positive.

Although the RT-PCR for SARS-CoV-2 in the CSF was negative, the data from the MRI and the CSF analysis, along with the positivity of the nasopharyngeal RT-PCR for SARS-CoV-2, led to the diagnosis of secondary encephalitis to SARS-CoV-2 infection. As a result, we decided to discontinue CSA, being immunosuppressive, during the infectious period.

For the next 10 days, the patient showed no recurrence of the seizure, did not require oxygen therapy, and did not present any new symptoms. After a second nasopharyngeal swab for SARS-CoV-2 that was negative, the patient was declared cured. The analysis of the CSF of a second lumbar punction analysis showed normal cellularity with normal glycorrhachia and proteinorachia. The patient was discharged with a maintenance oral dose of sodium valproate. Two weeks later, the patient had not experienced any recurrence of neurological symptoms and he had a persistent severe NS. Therefore, we decided to restart CSA treatment. Despite being under an anti-epileptic drug, the patient experienced

generalized tonic-clonic seizure one day after the immunosuppressant resumed treatment. This allowed us to rectify the diagnosis and relate the seizures to the CSA. A second cranial MRI (Figure 2) showed a progression of the previous lesions and the appearance of new cortical and subcortical hyperintensities in axial fluid attenuated inversion recovery-weighted and diffusion in the biparietal and right frontal lobe with an exaggerated meningeal gadolinium enhancement in front of these lesions.



Figure 2. Cortical and subcortical hyperintensities in axial fluid attenuated inversion recovery - weighted (A) and diffusion magnetic resonance imaging sequences sequences (B) in biparietal and right frontal lobe with an exaggerated meningeal gadolinium enhancement in front these lesions (C).

Imaging, as well as clinical data and the causal link with the taking of the treatment, the diagnosis of CSA-induced PRES, was retained. As an alternative to CSA, we opted for Rituximab at a dose of 1g per dose (two doses spaced two weeks apart) with good clinical and biological tolerance.

Discussion

Herein we reported the case of a 16-year-old boy whose treatment by CSA for a corticoresistant NS was complicated by a PRES. The diagnosis of CSA-related PRES was challenging since it was initially mistaken for COVID-19 encephalitis.

The primary pathophysiological process of PRES, first described by Hinchey et al. (2), was identified as vasogenic edema that denotes fluid extravasation from intracerebral capillaries (5). It is believed that the underlying cause of PRES may create a breakdown in cerebral autoregulation, leading to the leakage of fluid into the brain parenchyma (6). In these patients, either passive over-distension of the vessels due to elevations in blood pressure or direct toxic effects on the endothelium (7) blunt the myogenic response.

The consequent symptoms are variable ranging from confusion headache, nausea vomiting, and visual disturbance, to encephalopathy, and seizures associated with transient lesions on neuroimaging (8).

CSA was reported to be efficient in decreasing proteinuria in both steroid-dependent and steroid-resistant NS patients and is now largely used in nephrology (9). The association of PRES with CSA use has been previously described in NS patients, with successful recovery after drug withdrawal (5, 10, 11). Although the exact prevalence has not yet been determined, 5.7% of pediatric patients with NS who received cyclosporine developed PRES during the previous series of observations (3). Cyclosporine is responsible for a direct endothelial dysfunction resulting in a release of endothelin, prostacyclin, and thromboxane (12). These factors may cause microthrombi and damage the blood-brain barrier (2). In the presence of altered permeability, CSA may overcome the blood-brain barrier and enter the brain. In one study, the entrance of CSA into the brain inhibited gamma-aminobutyric acid neurotransmission in rats, resulting in convulsions (13).

It is worth mentioning that NS itself may be a predisposing factor for developing PRES in both adults and children (5). In addition to CSA, other factors seen in the nephrotic state could induce vasogenic edema due to decreased intravascular oncotic pressure, increased permeability of intracerebral capillaries, and fluid overload. Children with arterial hypertension, high-dose steroid treatments, hypercholesterolemia, high proteinuria levels, and low serum albumin levels are at a higher risk of PRES (14). Our case had all these risk factors mentioned above. On the other hand, he presented another possible explanation for seizures and PRES: SARS-CoV-2 infection. Indeed, SARS-CoV- 2 has recently been admitted to be a potential cause of PRES (15, 16). There are two possible explanations in this context. Firstly, SARS-CoV-2 is known to cause endothelial dysfunction (17), and secondly the virus binds directly to the angiotensin-converting enzyme 2 receptors, causing blood pressure and weakening the endothelial layer (18). Consequently, this leads to a weakened blood-brain barrier, which may result in dysfunction of the brain's autoregulation of cerebral circulation (16). The prevalence of PRES in COVID-19 patients is estimated to be between 1 and 4% (19). However, the resumption of seizures directly after reinitiating treatment made it possible to incriminate CSA as the cause of PRES in the reported case. Considering all of this, we believe that CSA and SARS-CoV-2 infection may have synergistic neurologic toxic effects in our case. Therefore, we may explain the short period between

the treatment initiation and the symptom installation. As reported in the literature, this period can range from one week to as long as 26 months (2, 20). Our patient experienced neurological manifestations four days after CSA initiation and was diagnosed with COVID-19 on the same day of symptoms onset. On another hand, we wonder if CSA had a protective effect against SARS-CoV- 2 in the reported case. Indeed, although he was immunosuppressed, he did not present with a severe form of infection. That may be explained by the capacity of CSA to inhibit the replication of several different coronaviruses in vitro, as demonstrated by several independent studies (19). The MRI is the gold standard exam to confirm PRES. It shows high-density signals in the white matter, especially in the occipital or temporal area (8). This preference distribution may be due to the paucity of sympathetic innervation in this vascular territory (21). In addition to parietooccipital involvement, high signal intensity areas may be seen in the frontal lobe in up to 82% of patients (13). Involvement of the anterior circulations and regions other than the parieto-occipital lobes like the cerebellum (34.2%) is, therefore, common (22). In this case, occasionally called atypical PRES.
Although the research highlights the difficulties in identifying PRES, it does not go into detail about the differential diagnostic procedure or offer a thorough explanation of how to differentiate PRES caused by CSA from other illnesses such as COVID-19 encephalitis.

Conclusion

Through this observation, we come to two conclusions. Firstly, infection with SARS-CoV-2 could be a differential diagnosis of a PRES related to anticalcineurins. Nevertheless, it is essential to establish the correct diagnosis because management depends on it. Secondly, CSA would be a protective factor against infection by SARS-CoV-2 and its cessation would not be justified during infection by this virus.

References

1. Fischer M, Schmutzhard E. Posterior reversible encephalopathy syndrome. J Neurol. 2017 Aug;264(8):1608-1616.
2. Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996 Feb 22;334(8):494-500.
3. De Oliveira RA, Fechine LM, Neto FC, Nicodemus JM, Silva GB Jr, Silva LS. Posterior reversible encephalopathy syndrome (PRES) induced by cyclosporine use in a patient with collapsing focal glomerulosclerosis. Int Urol Nephrol. 2008;40(4):1095-8.
4. Huenges K, Kolat P, Panholzer B, Haneya A. CSA-induced PRES after heart transplantation-report of two cases and review. Thorac Cardiovasc Surg Rep. 2021 Nov 10;10(1):e59-e60.
5. Ishikura K, Ikeda M, Hamasaki Y, Hataya H, Nishimura G, Hiramoto R et al. Nephrotic state as a risk factor for developing posterior reversible encephalopathy syndrome in paediatric patients with nephrotic syndrome. Nephrol Dial Transplant. 2008 Aug;23(8):2531-6.
6. Paulson OB, Waldemar G, Schmidt JF, Strandgaard S. Cerebral circulation under normal and pathologic conditions. Am J Cardiol. (1989) 63:2C–5C. 10.1016/0002-9149(89)90396-2.
7. Roy S, Gandhi AK, Jana M, Julka PK. Recurrent posterior reversible encephalopathy syndrome after chemotherapy in hematologic malignancy-posterior reversible encephalopathy syndrome can strike twice!!! J Cancer Res Ther. 2014 Apr-Jun;10(2):393-6.
8. Lee VH, Wijdicks EF, Manno EM, Rabinstein AA. Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Arch Neurol. 2008 Feb;65(2):205-10.
9. Tullus K, Webb H, Bagga A. Management of steroid-resistant nephrotic syndrome in children and adolescents. Lancet Child Adolesc Health. 2018 Dec;2(12):880-890.
10. Zhang Y, Zhou J, Chen Y. Posterior reversible encephalopathy syndrome in a child with steroid-resistant nephrotic syndrome: a case report and review of literature. Int J Clin Exp Pathol. 2014 Jun 15;7(7):4433-7.
11. Yamada A, Atsumi M, Tashiro A, Hiraiwa T, Ueda N. Recurrent posterior reversible encephalopathy syndrome in nephrotic syndrome: case report and review of the literature. Clin Nephrol. 2012 Nov;78(5):406-11.
12. Zoja C, Furci L, Ghilardi F, Zilio P, Benigni A, Remuzzi G. Cyclosporin-induced endothelial cell injury. Lab Invest. 1986 Oct;55(4):455-62.
13. Shuto H, Kataoka Y, Fujisaki K, Nakao T, Sueyasu M, Miura I et al. Inhibition of GABA system involved in cyclosporine-induced convulsions. Life Sci. 1999;65(9):879-87.
14. Zhou J, Zheng H, Zhong X, Wu D, Wang M, Tang X et al. Reversible posterior encephalopathy syndrome in children with nephrotic syndrome. Nephrology (Carlton). 2015 Nov;20(11):849-54.
15. Harapan BN, Yoo HJ. Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19). J Neurol. 2021 Sep;268(9):3059-3071.
16. Kishfy L, Casasola M, Banankhah P, Parvez A, Jan YJ, Shenoy AM et al. Posterior reversible encephalopathy syndrome (PRES) as a neurological association in severe Covid-19. J Neurol Sci. 2020 Jul 15;414:116943.
17. Nappi F, Avtaar Singh SS. Endothelial Dysfunction in SARS-CoV-2 Infection. Biomedicines. 2022 Mar 11;10(3):654.
18. Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong JC, Turner AJ et al. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. Circ Res. 2020 May 8;126(10):1456-1474.
19. Gewirtz AN, Gao V, Parauda SC, Robbins MS. Posterior reversible encephalopathy syndrome. Curr Pain Headache Rep. 2021 Feb 25;25(3):19.
20. Heiss S, Krampla W, Klauser-Braun R. A patient recently transplanted with a living donor kidney develops severe neurological symptoms. Nephrol Dial Transplant. 2006 Jul;21(7):2017-9.
21. Poulsen NN, von Brunn A, Hornum M, Blomberg Jensen M. Cyclosporine and COVID-19: Risk or favorable? Am J Transplant. 2020 Nov;20(11):2975-2982.
22. McKinney AM, Short J, Truwit CL, McKinney ZJ, Kozak OS, SantaCruz KS et al. Posterior reversible encephalopathy syndrome: incidence of atypical regions of involvement and imaging findings. AJR Am J Roentgenol. 2007 Oct;189(4):904-12.